A: The dosage form of this product is in the form of a tablet
Thus, resolving a hemostatic defect, the hallmark of which is a markedly prolonged bleeding time, BPC 157 reduced the bleeding times in the tail amputation model, heparin and partly warfarin rats, but unlike in normal rats, did not reduce bleeding time in heparin and warfarin rats when previously L-arginine or L-NAME was given
Studied since the early 1990s for gut healing, tendon repair, and systemic recovery, BPC-157 has never been placed on the formal Category 1 list yet it has one of the most extensive safety records in the peptide literature
Because research-market material is sold outside any approved supply chain, its identity and purity are unverified: published trial data describe a characterized study drug, not the contents of an arbitrary vial, so identity confirmation (for example by mass spectrometry and HPLC) and a batch certificate of analysis are the minimum a rigorous research setting should require